New PET scans reveal how experimental drug reshapes lung vessels in PAH
NCT ID NCT07357974
First seen Feb 01, 2026 · Last updated Jun 13, 2026 · Updated 25 times
Summary
This pilot study will use special PET/CT scans to see how the experimental drug sotatercept affects blood vessel remodeling in the lungs and heart of people with pulmonary arterial hypertension (PAH). About 15 adults with PAH will receive sotatercept and have imaging at the start and after 24 weeks. The goal is to measure changes in fibroblast activity and lung blood flow, not to treat symptoms directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Brest
Brest, Finistere, 29200, France
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.